• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NEOG

    Neogen Corporation

    Subscribe to $NEOG
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.

    IPO Year: 1989

    Exchange: NASDAQ

    Website: neogen.com

    Recent Analyst Ratings for Neogen Corporation

    DatePrice TargetRatingAnalyst
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    See more ratings

    Neogen Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wainer Andrea F was granted 6,090 shares (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      6/4/25 4:08:39 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Wainer Andrea F

      3 - NEOGEN CORP (0000711377) (Issuer)

      6/4/25 4:01:51 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer Naemura David H. was granted 52,724 shares, increasing direct ownership by 86% to 114,158 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      6/4/25 12:54:50 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Legal Officer Rocklin Amy M was granted 43,585 shares, increasing direct ownership by 118% to 80,436 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      6/4/25 11:43:14 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Accounting Officer Moylan John Patrick was granted 26,362 shares, increasing direct ownership by 264% to 36,362 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      6/4/25 11:29:13 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Gupta Aashima bought $99,987 worth of shares (16,000 units at $6.25), increasing direct ownership by 270% to 21,917 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      5/12/25 2:30:47 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $5.15 and covered exercise/tax liability with 1,603 shares, increasing direct ownership by 30% to 12,955 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      5/2/25 1:48:58 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CEO Adent John Edward exercised 2,112 shares at a strike of $5.16, increasing direct ownership by 0.78% to 271,276 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:39:59 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operating Officer Jones Douglas Edward exercised 845 shares at a strike of $5.16 and covered exercise/tax liability with 291 shares, increasing direct ownership by 0.78% to 71,713 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:34:22 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Legal Officer Rocklin Amy M exercised 564 shares at a strike of $5.16, increasing direct ownership by 2% to 36,851 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:29:07 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Neogen Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Neogen with a new price target

      Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

      12/19/24 8:18:19 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Wells Fargo initiated coverage on Neogen with a new price target

      Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

      6/16/23 7:34:39 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen upgraded by William Blair

      William Blair upgraded Neogen from Mkt Perform to Outperform

      11/22/22 8:02:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Piper Sandler initiated coverage on Neogen with a new price target

      Piper Sandler initiated coverage of Neogen with a rating of Neutral and set a new price target of $25.00

      7/12/22 7:33:12 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care